Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 183 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Women Contraception Clear all

Conditions: HIV Infections, Pregnancy
Interventions: Lopinavir/ritonavir, Ortho Novum 1/35, Ortho Evra; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Honolulu, Hawaii + 3 more

Conditions: Chemical Teratogen Exposure, Contraception Behavior, Contraception
Interventions: EMR Referral, CTIS Counseling, Baseline Questionnaire, Contraception Provision Appointment, 3 Month Follow Up Questionnaire, 6 Month Follow Up Questionnaire; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: San Diego, California

Conditions: Intrauterine Devices
Interventions: Intrauterine device; Device
Lead sponsor: Bayer; Industry
Eligibility: Up to 50 Years · Female only
Enrollment: 326,658 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 4
States / cities: Oakland, California • Pasadena, California • Indianapolis, Indiana + 1 more

Conditions: Contraception
Interventions: TV-46046, Depo-subQ Provera; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Cypress, California • San Antonio, Texas

Conditions: Postpartum Period, Contraception Behavior, Women's Health, Primary Health Care
Interventions: RLPT; Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 15 Years to 49 Years · Female only
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Contraception
Interventions: Ulipristal Acetate, Combined Oral Contraceptive Pill; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 39 Years · Female only
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: New York, New York

Conditions: Postpartum Care
Interventions: Healthy Beyond Pregnancy, Pre-Scheduled Postpartum Visit, Attention Control; Behavioral · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Years to 50 Years · Female only
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Preconception Care
Interventions: "video doctor," computer module; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 446 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Contraception
Interventions: Gestodene/EE Patch (BAY86-5016); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,502 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 63
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 54 more

Conditions: Pregnancy
Interventions: Not listed
Lead sponsor: University of California, San Francisco; Other
Eligibility: 15 Years to 24 Years · Female only
Enrollment: 1,387 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 5
States / cities: Hayward, California • Oakland, California • Richmond, California + 2 more

Conditions: Family Dynamics, Trust in Healthcare System, Family Structure, Health Literacy, Contraception, Maternal Behavior, Postpartum Mood Disturbance
Interventions: The PEN-3 Intervention Model; Behavioral
Lead sponsor: Jackson State University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Contraception
Interventions: 15 mg E4/3 mg DRSP; Drug
Lead sponsor: Estetra; Industry
Eligibility: 16 Years to 50 Years · Female only
Enrollment: 2,148 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Epilepsy
Interventions: Non-interventional; Other
Lead sponsor: Neuroendocrine Associates P.C.; Other
Eligibility: 18 Years to 47 Years · Female only
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Wellesley, Massachusetts • New York, New York

Conditions: Opioid Use Disorder
Interventions: Computer-adaptive SAFE, Face-to-face SAFE, Usual Care; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy Men, Male Contraception, Healthy Women, Product Transference
Interventions: Nestorone + Testosterone Combination Gel; Drug
Lead sponsor: Kimberly Myer; Other
Eligibility: 18 Years to 50 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 2
States / cities: Torrance, California • Seattle, Washington

Conditions: Alcohol Exposed Pregnancy, Unplanned Pregnancy, Alcohol Use, Unspecified, Contraception Use, Sexual Behavior
Interventions: CARRII Native Rapid Pilot Testing; Behavioral
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 44 Years · Female only
Enrollment: 407 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Contraception
Interventions: AMPHORA; Drug
Lead sponsor: Evofem Inc.; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 1,384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 87
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 67 more

Conditions: Contraception
Interventions: Household Visits, Small Groups; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 13 Years and older
Enrollment: 2,898 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: San Diego, California

Conditions: Contraceptives, Oral
Interventions: Lybrel, Doxycycline, Oracea, Placebo, Doxycycline 100bid x5 days at the time of bleeding, Subantimicrobial doxycycline daily, placebo daily; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 131 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Honolulu, Hawaii • Portland, Oregon

Conditions: Contraception
Interventions: Levonorgestrel (BAY98-7196); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 1,471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 79
States / cities: Mobile, Alabama • Chandler, Arizona • Mesa, Arizona + 67 more

Conditions: Pregnancy Prevention
Interventions: DR-103; Drug
Lead sponsor: Teva Women's Health; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 3,597 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 94
States / cities: Montgomery, Alabama • Phoenix, Arizona • Tucson, Arizona + 83 more

Conditions: Unplanned Pregnancy
Interventions: Counseling Intervention; Behavioral
Lead sponsor: University of Chicago; Other
Eligibility: 15 Years to 29 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Contraception, Fetal Growth Retardation, Infant, Small for Gestational Age, Obesity
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Vulvodynia
Interventions: CO2 laser, Lidocaine patch 5%; Device · Drug
Lead sponsor: Atlantic Health System; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Denville, New Jersey

Search by objective public record fields.

Drug Interactions Between Lopinavir/Ritonavir and Oral or Patch Contraceptives in HIV Infected Women

EMR Referrals for Teratogen and Contraceptive Counseling for Category D or X Medication Users: RCT

Study on Medical Records of Women Using an Intrauterine Device (IUD) to Analyze the Risks That the IUD Will be Expelled or Perforates the Womb in Relation to Breastfeeding, the Point in Time When the IUD Was Inserted After Childbirth and in Relation to Different Types of IUDs

A Study to Evaluate the Pharmacokinetics (PK) of Medroxyprogesterone Acetate Following an Injection of TV-46046 in Healthy Women of Reproductive Age

Use of a Reproductive Life Planning Tool at the Pediatric Well-Baby Visit With Postpartum Women

Compare Daily Ulipristal Acetate and Combined Oral Contraceptive Effects on Breast Epithelial Cell Proliferation

Care After Pregnancy Study (CAPS): Engaging Women in Postpartum Care

Computer-assisted Preventive Health Education for Women of Reproductive Age in Urgent Care Settings

Study Investigating the Efficacy and Safety of a Contraceptive Patch for 13 Cycles

Combined Hormonal Contraceptive Use in High Risk Women: A Longitudinal Study

Patient-clinical Linkages to Improve Trust and Engagement in Postpartum Healthcare

E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study

Epilepsy Birth Control Registry

Sex and Female Empowerment

Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males

Optimizing a Digital AEP Risk Intervention With Native Women and Communities

AMP002 Phase III Contraceptive Study

Evaluating Household Visits and Small Groups to Increase Contraception Use Among Married Adolescent Girls in Rural Niger

A Study of Continuous Oral Contraceptives and Doxycycline

Safety and Contraceptive Efficacy of an Intravaginal Ring With LNG (Levonorgestrel) Over One Year in Healthy Women

A Study to Evaluate the Efficacy and Safety of DR-103 for the Prevention of Pregnancy

Use of Motivational Interviewing to Increase Contraception Use Among Young Women

Obesity and Oral Contraceptive Failure

CO2 Laser vs Lidocaine for Vestibulodynia in Premenopausal Women